

MEDICATIONS FOR OPIOID USE DISORDER

Leslie Dabovich Dempsey, MD
*Southern Colorado Family Medicine
Faculty & Director of Obstetrics
ICWB Co-clinical Lead*

NEW



OBJECTIVES

Update our understanding of common terms

Review 3 major categories of treatment medications:

- MOA

- Risks/Benefits

- Dosing Strategies

A quick look at supportive medications

A Brief word on treatment settings


Followup Care Basics



A ROSE BY ANY OTHER NAME . . .

- OUD - Opioid Use Disorder
- Dependence
- MOUD - Medications for Opioid Use Disorder
- MAT - Medication-Assisted Treatment
- NAS - Neonatal Abstinence Syndrome

DSM V CRITERIA FOR DX OF OUD



Loss of Control	1 - More and for longer than intended 2 - Unable to cut back or control use 3 - A lot of time spent obtaining, use, recovering 4 - Craving, or a strong desire to use
Social Impairment	5 - Causing failure of obligations at work, school, or home 6 - Contributing to social/interpersonal problems 7 - Important social, occupation or recreation activities given up to use
Risky Use	8- Use in physically hazardous situations 9- Use w/ knowledge that it is contributing to physical and psychological problems
Tol & WD	10 - tolerance 11 - withdrawal

Mild (1-3), Moderate (4-5), Severe (6+)

MEDICATIONS FOR OPIOID OVERDOSE, WITHDRAWAL, & ADDICTION

Medications for opioid **overdose**, **withdrawal**, and **addiction** are safe, effective and save lives.

The National Institute on Drug Abuse supports research to develop new medicines and delivery systems to treat opioid use disorder and other substance use disorders, as well as other complications of substance use (including withdrawal and overdose), to help people choose treatments that are right for them.

FDA-approved medications for opioid addiction, overdose, and withdrawal work in various ways.

- ⊖ **Opioid Receptor Agonist**
Medications attach to opioid receptors in the brain to block withdrawal symptoms and cravings.
- ⊖ **Opioid Receptor Partial Agonist**
Medications attach to and partially activate opioid receptors in the brain to ease withdrawal symptoms and cravings.
- ⊖ **Opioid Receptor Antagonist**
Medications block activity of opioid receptors in the brain to prevent euphoric effects (the high) of opioids and alcohol and help reduce cravings.
- ⊖ **Adrenergic Receptor Agonist**
A medication that attaches to and activates adrenergic receptors in the brain and helps alleviate withdrawal symptoms.

REDUCES OPIOID USE AND CRAVINGS

Methadone

Daily liquid or tablet



Naltrexone

Monthly Injection



Buprenorphine

Daily tablet
Monthly injection



Buprenorphine/ Naloxone

Daily film under the tongue or tablet



TREATS WITHDRAWAL SYMPTOMS

Lofexidine

As-needed tablet



REVERSES OVERDOSE

Naloxone

Emergency nasal spray or injection




METHADONE

The "gold standard" or the "OG"

Formulations: tablets (pain), liquid (OUD trt), wafer (rare)

- + Full agonist, pain control, no "max" dose, easy to start, no risk or precipitated withdrawal, long half life (15-60 h → 5d to ss)
- for OUD treat need to pick up daily*, sedation, stigma, QTc prolongation, medication interactions (a lot of abx), overdose due to long half life



METHADONE


Dosing:

Start at 30-40mg typically

Average therapeutic dose often 80-120mg/d*

Inpatient: Start at 30mg, add 10mg every 4 hours that pt not sedated to max of 50mg on 1st day

Outpatient: OTP required



BUPRENORPHINE

PARTIAL AGONIST

Formulations: tablet (SL), film (B), injectable (SQ, IV)

+

accessible to any prescriber in CO* (no OTP needed)

decreased risk of sedation and respiratory depression

pain control

long acting (24-26h)

high affinity for mu receptor

-


Max dose of 24mg *

Taste?

Nausea/headaches

w/ and w/o precipitated withdrawal

Less effective w/ fentanyl due to ceiling effect?



BUPRENORPHINE

PARTIAL AGONIST

Low - small and gradually increasing doses while CONTINUING/TAPERING full agonist over 2-7 days

Traditional *

Start 2-4mg when COWS score 12 and above


Re-dose with 2mg every 2-4 hours until COWS score < 5, to max of 24mg*

Day 2 - give total used on day 1 and give BID

Increase prn


High -not ideal in pregnancy. Mostly seen in ED

Wait for severe w/d, start 16mg SL, redoses if slight improvement in 1 hour, reassess if no improvement



Treatment of bup precipitated withdrawal

(Sudden, significant worsening of withdrawal soon after bup administration.)



Adjuvants:

OK but should not delay or replace bup. Use sparingly with appropriate caution.

Benzodiazepines:

- Lorazepam 2 mg PO/IV

Antipsychotics:

- Olanzapine 5 mg PO/IM

Alpha-agonists:

- Clonidine 0.1-0.3 mg PO

D2/D3 agonists:

- Pramipexole 0.25 mg PO

Gabapentinoids:

- Pregabalin 150 mg PO

Escalate level of care to manage potential moderate to deep sedation including cardiac, pulse oximetry, and end tidal CO2 monitoring:

1. Ketamine (0.3 mg/kg IV slow push q 15 minutes and/or infusion).
2. Fentanyl 200 mcg IV q10 minutes. Total dose of > 2000 mcg has been reported.

BUPRENORPHINE

PARTIAL AGONIST

<u>SLOW</u> BUPRENORPHINE MICROINDUCTION RECOMMENDATION⁻⁴			
DAY	DATE	SUBOXONE DOSE	CURRENT SUBSTANCE RECOMMENDATIONS
Day 1		¼ film once daily	Continue current dose/use
Day 2		¼ film twice daily	Continue current dose/use
Day 3		½ film twice daily	Continue current dose/use
Day 4		1 film twice daily	Reduce dose/use by 25%
Day 5		1 ½ films twice daily	Reduce dose/use by 25%
Day 6		2 film's twice daily	Reduce dose/use by 25%
Day 7		3 film's twice daily	Reduce dose/use by 50%
Day 8 and beyond dosing to be filled in by provider at follow up appointments			
Day 8			Reduce dose/use by 50%
Day 9			Reduce dose/use by 50%
Day 10			Reduce dose/use by 50-75%
Day 11			Reduce dose/use by 50-75%
Day 12			Reduce dose/use by 75%
Day 13			Reduce dose/use by 75%
Day 14			STOP
Days 15 – beyond			STOP

NALTREXONE

ANTAGONIST


Formulation: IM inj (for OUD), daily tablet (AUD)

+ no physical dependence as antagonist (blocks receptor)

HIGH affinity and competitive binding

Accessible

- Need 7-10d opioid free prior before starting, intolerance due to nausea/HAs, pain management issues when indicated



ADJUNCT TREATMENTS (+/-)

- Clonidine 0.1 mg orally q4h PRN restlessness, hot/cold flashes or anxiety
- Hydroxyzine 25-50 mg orally q6h PRN anxiety or insomnia
- Ondansetron 4 mg orally q6h PRN nausea
- Dicyclomine 10 mg orally TID PRN abdominal cramping
- Trazodone 50-100 mg orally qHS PRN insomnia
- Acetaminophen 500-1000 mg orally q6h PRN headache, pain
- Gabapentin 300 mg orally TID PRN restless legs, anxiety, agitation
- Promethazine 12.5-25 mg orally q6H PRN nausea (if preferred to ondansetron, or not having success with ondansetron)

TO BE OR NOT TO BE

In the hospital

There is no universally accepted protocol for where buprenorphine **initiations** should occur for pregnant women:

- Home
 - Clinic
 - OTP
 - ER/OB Triage
 - L&D
 - Med/Psych Units
 - Other?
- Hybrid Clinic/Home



FOLLOWUP CARE

Medication:

Buprenorphine - apt in 5-7 days, enough medication to get to apt

Methadone: coordinate with OTP for next day dose, weekends/holidays *

Post Partum Appointments - increased intensity rec'd

Peer Support

Social work

OUD/SUD in patient's problem list

NALOXONE !



THANK YOU

- *To Dr Klie and MOMS+ for allowing me to borrow some of their content and graphics.*
- *To all those listening for being my 1st audience in this new role!*

Leslie Dabovich Dempsey, MD

Leslie.Dempsey@commonspirit.org

QUESTIONS?